The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study

被引:11
|
作者
Schosser, Alexandra [1 ,2 ]
Carlberg, Laura [1 ]
Calati, Raffaella [3 ]
Serretti, Alessandro [4 ]
Massat, Isabel [5 ]
Spindelegger, Christoph [1 ]
Linotte, Sylvie [6 ]
Mendlewicz, Julien [6 ]
Souery, Daniel [7 ,8 ]
Zohar, Joseph [9 ]
Montgomery, Stuart [10 ]
Kasper, Siegfried [1 ]
机构
[1] Med Univ Vienna, Dept Psychiat & Psychotherapy, Wahringer Gurtel 18-20, A-1090 Vienna, Austria
[2] Zentrum Seel Gesundheit, Leopoldau, Austria
[3] Univ Montpellier, FondaMental Fdn, INSERM, U1061, Montpellier, France
[4] Univ Bologna, Dept Biomed & NeuroMotor Sci, Bologna, Italy
[5] Natl Fund Sci Res, Lab Expt Neurol, Brussels, Belgium
[6] Univ Libre Bruxelles, Brussels, Belgium
[7] Univ Libre Bruxelles, Lab Psychol Med, Brussels, Belgium
[8] Psy Pluriel, Ctr Europe Psychol Med, Brussels, Belgium
[9] Chaim Sheba Med Ctr, Tel Hashomer, Israel
[10] Univ London, Sch Med, Imperial Coll, London, England
来源
关键词
BDNF; suicidality; depression; pharmacogenetic; NEUROTROPHIC FACTOR; GENE POLYMORPHISMS; BRAIN; BEHAVIOR; ASSOCIATION; VAL66MET; SIZE;
D O I
10.1093/ijnp/pyx028
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Numerous studies have reported associations between the brain-derived neurotrophic factor (BDNF) gene and psychiatric disorders, including suicidal behavior, although with conflicting results. Methods: A total of 250 major depressive disorder patients were collected in the context of a European multicenter resistant depression study and treated with antidepressants at adequate doses for at least 4 weeks. Suicidality was assessed using the Mini International Neuropsychiatric Interview and Hamilton Rating Scale for Depression, and treatment response using the HAM-D. Genotyping was performed for the functional Val66Met polymorphism (rs6265) and 7 additional tagging single nucleotide polymorphisms within the BDNF gene. Results: Neither BDNF single markers nor haplotypes were found to be associated with suicide risk and lifetime history of suicide attempts. Gender-specific analyses revealed nonsignificant single marker (rs908867) and haplotypic association with suicide risk in males after multiple testing correction. Analyzing treatment response phenotypes, the functional Val66Met polymorphism as well as rs10501087 showed significant genotypic and haplotypic association with suicide risk in remitters (n = 34, 13.6%). Conclusions: Considering the sample size, the present findings need to be replicated in larger samples to confirm or refute a role of BDNF in the investigated suicidal behavior phenotypes.
引用
收藏
页码:782 / 787
页数:6
相关论文
共 50 条
  • [31] Decreased fronto-limbic volumes in treatment-resistant major depressive disorder
    Serra-Blasco, M.
    Portella, M. J.
    De Diego-Adelino, J.
    Vives-Gilabert, Y.
    Gomez-Anson, B.
    Santos, A.
    Puigdemont, D.
    Alvarez, E.
    Perez, V.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S239 - S240
  • [32] Safety and efficacy of olanzapine plus fluoxetine in treatment-resistant major depressive disorder
    Shelton, R
    Tollefson, GD
    Tohen, M
    Jacobs, T
    Buras, W
    Spencer, K
    Gannon, KS
    Stahl, S
    [J]. SCHIZOPHRENIA RESEARCH, 1999, 36 (1-3) : 297 - 298
  • [33] Treatment-resistant major depressive disorder: Canadian expert consensus on definition and assessment
    Rybak, Yuri E.
    Lai, Ka S. P.
    Ramasubbu, Rajamannar
    Blumberger, Daniel M.
    Chan, Peter
    Delva, Nicholas
    Giacobbe, Peter
    Gosselin, Caroline
    Kennedy, Sidney H.
    Iskandar, Hani
    McInerney, Shane
    Ravitz, Paula
    Sharma, Verinder
    Zaretsky, Ari
    Burhan, Amer M.
    [J]. DEPRESSION AND ANXIETY, 2021, 38 (04) : 456 - 467
  • [34] Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder
    Papakostas, G. I.
    Ionescu, D. F.
    [J]. MOLECULAR PSYCHIATRY, 2015, 20 (10) : 1142 - 1150
  • [35] Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder
    G I Papakostas
    D F Ionescu
    [J]. Molecular Psychiatry, 2015, 20 : 1142 - 1150
  • [36] The quest for optimal ketamine dosing formula in treatment-resistant major depressive disorder
    Kwasna, Julia
    Cubala, Wieslaw Jerzy
    Kwasny, Aleksander
    Wilkowska, Alina
    [J]. PHARMACOLOGICAL REPORTS, 2024,
  • [37] Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder
    Ivanova, Jasmina I.
    Birnbaum, Howard G.
    Kidolezi, Yohanne
    Subramanian, Ganesh
    Khan, Sajjad A.
    Stensland, Michael D.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (10) : 2475 - 2484
  • [38] An open study of triiodothyronine augmentation of selective serotonin Reuptake inhibitors in treatment-resistant major depressive disorder
    Iosifescu, DV
    Nierenberg, AA
    Mischoulon, D
    Perlis, RH
    Papakostas, GI
    Ryan, JL
    Alpert, JE
    Fava, M
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (08) : 1038 - 1042
  • [39] THE IMPACT OF ANXIETY SENSITIVITY ON SUICIDALITY IN ADOLESCENTS WITH MAJOR DEPRESSIVE DISORDER
    Bilgic, Ayhan
    Yilmaz, Savas
    Herguner, Sabri
    [J]. PSYCHIATRIA DANUBINA, 2017, 29 (04) : 473 - 479
  • [40] Sertoli cell therapy: A novel possible treatment strategy for treatment-resistant major depressive disorder
    Loftis, J. M.
    [J]. MEDICAL HYPOTHESES, 2011, 77 (01) : 35 - 42